Ipamorelin was originally investigated for its potential benefits on gastrointestinal function, making it one of the most well-researched peptides for digestive health. This peptide was first investigated as a potential treatment for postoperative ileus, a condition that can lead to bowel obstruction because it causes the bowels to stop working after an individual has undergone bowel surgery.
These results suggest that ipamorelin accelerates gastric emptying in a rodent model of postoperative ileus through the stimulation of gastric contractility by activating a ghrelin receptor-mediated mechanism involving cholinergic excitatory neurons.
In summary, we have shown for the first time in vivo that ipamorelin significantly accelerates gastric emptying in a rodent model of gastroparesis induced by abdominal surgery. In tissue isolated from the gastric fundus, ipamorelin normalized the contractile response to cholinergic neural stimulation. These results suggest that ipamorelin improves delayed gastric emptying by stimulating gastric contractility via GRLN receptor-mediated mechanisms located on cholinergic neurons. In conclusion, our study highlights the profound effects of ipamorelin on the upper GI tract and suggests that the compound may be of interest as a prokinetic agent to treat GI dysmotility, characterized by delayed gastric emptying and slow upper GI transit.
Ghrelin and ghrelin mimetics stimulate appetite and enhance gastric motility. The present study investigates whether ipamorelin, a selective growth hormone secretagogue and agonist of the ghrelin receptor, would accelerate gastrointestinal transit and ameliorate the symptoms in a rodent model of postoperative ileus (POI).
Compared with the vehicle, a single dose of ipamorelin (1 mg/kg) or GHRP-6 (20 microg/kg) decreased the time to the first bowel movement but had no effect on cumulative fecal output, food intake, or body weight gain measured 48 h after the surgery. In contrast, repetitive dosing of ipamorelin (0.1 or 1 mg/kg) significantly increased the cumulative fecal pellet output, food intake, and body weight gain. The results suggest that postsurgical intravenous infusions of ipamorelin may ameliorate the symptoms in patients with POI.
As mentioned previously, the GHSR-1a receptor is also present in a number of regions outside the brain including the gastrointestinal tract. Several studies have evaluated ipamorelin’s ability to improve gastric motility in the setting of postoperative ileus. Greenwood-Van Meerveld et al. assessed ipamorelin’s effects in rodent models with induced postoperative ileus (POI). The authors observed that ipamorelin had a dose-dependent effect on improving gastric emptying and thereby reversed POI-induced delayed gastrointestinal transit.
Peptides, such as Sermorelin and Ipamorelin, play a crucial role in gut health. They stimulate the release of growth hormones, which can influence various metabolic processes in the gut. Understanding their function can help in managing gut-related health conditions.
Peptides derived from food play a crucial role in maintaining gut health and its proper functioning. In terms of the biological functions they are involved in are modulation of the barrier function, immune responses and modulation of the gut microbiota. Interestingly, gut peptides can suppress the growth of pro-obesity gut bacteria and can facilitate the proliferation of anti-obesity effects. This again, highlights the supportive role of the peptides in the gut to our health and overall wellbeing. Peptides can also modulate signalling pathways which contribute to protective and regenerative actions in the gut.
Metabolic and Digestive Benefits: Ipamorelin improves digestive health and helps regulate blood sugar levels, contributing to overall metabolic well-being.
Support for organ health: A small-scale study suggests that ipamorelin may contribute to organ health, especially the digestive system.
Anamorelin and ipamorelin administered i.p. had beneficial effects in alleviating cisplatin-induced weight loss during delayed phase.These findings demonstrate Ipamorelin’s potential to support gastrointestinal function during challenging clinical circumstances such as chemotherapy.
